%PDF-1.4
%
28 0 obj
<>
endobj
25 0 obj
<>
endobj
81 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-08-05T16:33:42Z
2024-03-29T08:10:54-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-29T08:10:54-07:00
application/pdf
Heather
2004-949.sept
uuid:47e29192-1dd2-11b2-0a00-d808275dc400
uuid:47e29194-1dd2-11b2-0a00-810000000000
endstream
endobj
14 0 obj
<>
endobj
15 0 obj
<>
endobj
29 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
95 0 obj
[99 0 R]
endobj
96 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
0.2487 Tw 10 0 0 10 53.5 735.3264 Tm
[(all time points, were about 50% and 73%, respectively)65 (,)]TJ
-0.0125 Tw 0 -1.2 TD
(when evaluated on a separate cohort of patients independent)Tj
0.02499 Tw T*
(from the cohort used in the model building.)Tj
/TT1 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/TT0 1 Tf
0 Tc 0.2177 Tw 8 0 0 8 53.5 677.3264 Tm
(The authors thank Patty Hall, RN, BSN, for study conduct and Linda)Tj
-0.00011 Tc 0.02499 Tw 0 -1.25 TD
(Melvin, BA, for assistance in manuscript preparation.)Tj
/TT1 1 Tf
0 Tw 10 0 0 10 53.5 643.3264 Tm
(REFERENCES)Tj
/TT0 1 Tf
0.02499 Tw 8 0 0 8 60.5 633.3264 Tm
[(1.)-875.1 (Anderson JJ, Baron G, van der Heijde D, Felson DT)73.9 (, Dougados M.)]TJ
0 Tc 1.675 -1.25 Td
(Ankylosing spondylitis assessment group preliminary definition of)Tj
T*
[(short-term improvement in ankylosing spondylitis. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(2001;44:1876-86.)Tj
0.02499 Tw -1.675 -1.25 Td
[(2.)-875 (Davis JC, van der Heijde D, Braun J, et al. Recombinant human)]TJ
-0.00011 Tc 1.675 -1.25 Td
(tumor necrosis factor receptor \(etanercept\) for treating ankylosing)Tj
0 Tc T*
[(spondylitis: a randomized controlled trial. )54.8 (Arthritis Rheum)]TJ
0 Tw T*
(2003;48:3230-6.)Tj
0.0249 Tw 31.325 21.671 Td
[(3.)-875 (Calin )54.8 (A, Garrett S, )17.7 (Whitelock H, et al. )54.8 (A)-219.8 (new approach to defining)]TJ
1.675 -1.25 Td
(functional ability in ankylosing spondylitis: the development of the)Tj
T*
[(Bath )54.9 (Ankylosing Spondylitis Functional Index. J Rheumatol)]TJ
0 Tw T*
(1994;21:2281-5.)Tj
0.0249 Tw -1.675 -1.25 Td
[(4.)-875 (Liang KY)128.9 (, Zeger SL. Longitudinal data analysis using generalized)]TJ
1.675 -1.25 Td
(linear models. Biometrika 1986;73:12-22.)Tj
-1.675 -1.25 Td
[(5.)-875 (Agresti )54.8 (A. Categorical data analysis. New )36.8 (Y)100.1 (ork: John )17.7 (W)39.8 (iley &)]TJ
1.675 -1.25 Td
(Sons; 1990.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (Garrett S, Jenkinson )17.7 (T)73.9 (,)-0.1 ( Kennedy LG, )17.7 (Whitelock H, Gaisford P)110.7 (,)]TJ
0 Tc 1.675 -1.25 Td
[(Calin )54.9 (A. )54.9 (A)-219.8 (new approach to defining disease status in ankylosing)]TJ
-0.00011 Tc T*
[(spondylitis: the Bath )54.8 (Ankylosing Spondylitis Disease )54.8 (Activity)]TJ
0 Tc T*
(Index. J Rheumatol 1994;21:2286-91.)Tj
-1.675 -1.25 Td
[(7.)-875 (Braun J, Pham )17.7 (T)74 (, Sieper J, et al. International )54.8 (ASAS consensus)]TJ
-0.00011 Tc 1.675 -1.25 Td
(statement for the use of anti-tumour necrosis factor agents in)Tj
0 Tc T*
[(patients with ankylosing spondylitis. )54.8 (Ann Rheum Dis )]TJ
0 Tw T*
(2003;62:817-24.)Tj
ET
/CS0 CS 0 0 0 1 SCN
53.46 77 m
558.47 77 l
S
0 0 0 0 scn
52.32 70.16 64.18 -15.66 re
f*
BT
0 0 0 1 scn
/TT2 1 Tf
8 0 0 8 53.3216 57.2343 Tm
(1754)Tj
ET
0 0 0 0 scn
355.5 70.16 203 -15.66 re
f*
BT
0 0 0 1 scn
/TT2 1 Tf
0.02499 Tw 8 0 0 8 423.8613 57.2343 Tm
(The Journal of Rheumatology 2005; 32:9)Tj
ET
0 0 0 0 scn
/GS0 gs
104.13 82.08 407.5 -10.83 re
f*
0.5 w
104.13 82.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 29, 2024 from )Tj
ET
endstream
endobj
72 0 obj
<>
endobj
86 0 obj
<>
endobj
35 0 obj
<>
endobj
10 0 obj
<>
endobj
36 0 obj
<>
endobj
33 0 obj
<>
endobj
67 0 obj
<>stream
HVpg~s""4[.E\Rq&S,snKk6m);nծi'A3;=_|{y;_ wKY&|C@E݇cu`%@UOXKW֯bZ (YK#fJۯkʣWQ| Sʝ/5囀1kvQ OJP*,7gW%~/`f1=ou%gɄujɲ]˓sn!Zs-zA|^@fpNLZk>{idh|xmuX
![JhHAG; PK㸂"JdA"W,C)neK:ZwǤpX*U|\$uop['H!^úL-:t`Y=pM~LQzut%ywfFsMKdƥw쐒>!>.]gĴnղEdӡC74c0-*?QM!O??g<=MǞ"FLg11\^մЊ/̫¯!eAx
j6qj[ڑM%p=|f
oئf|7*pg"Șjlhl:sLGCJ\]b801Tm2xkƿv%h[lFS 45~[
4%1|S,g`ݦkSoJ4e~<1hbBDO?j>=8.p/$or];.Goŝِ$Œ5s+aIMSZ^<| "0"
U>t@0]S-5Ѓ?m4o> 4k1?^~|ah632t)aHm`XӝYi&1R!ub].e=J$똚Sm˾G